50% of mortalities attributable to cardiac causes are accounted for by cardiac arrhythmias occurring either independently or as a result of other underlying heart diseases.Classic pharmacological antiarrhythmic approaches suffer from poor efficacy and risk of serious complications.Recently, the notion of "upstream therapy", targeting the processes involved in the development of arrhythmic substrates, has increasingly become the focus of attention.